2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle C
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Biological Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Animal Model
PAPER

1044 Integrated functional genomics identify mechanisms of response and resistance to RAS inhibition in multiple myeloma

Torsten Steinbrunn, MD, PhD, Omar S Al-Odat2, Arnold Bolomsky3, Ricardo De Matos Simoes, PhD4, Eleni Anastasakou5, Ryosuke Shirasaki, MD6, Michele Ceribelli7, Olga Dashevsky, PhD8, Huihui Tang, PhD9, Shizuka Yamano10, Oliver Bohorquez11, Brian J Glassner12, Vikas Gupta, MD, PhD13, James G Christensen14, Andrew Aguirre15, Jonathan Licht, MD16, Benjamin Gabriel Barwick, PhD17, Lawrence H Boise, PhD18, Craig Thomas19, Constantine Mitsiades, MD, PhD20, Ryan M Young, PhD21
1 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
2 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
3 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
4 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
5 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
6 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medical Oncology, Teikyo University Hospital, Tokyo, Japan, Department of Medicine, Harvard Medical School, Boston, MA, United States
7 Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States
8 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
9 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
10 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
11 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
12 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
13 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States
14 Mirati Therapeutics, Inc., San Diego, United States
15 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States
16 Van Andel Institute, Grand Rapids, MI, United States
17 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States
18 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States
19 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
20 Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States, Department of Medicine, Harvard Medical School, Boston, MA, United States, Ludwig Center at Harvard Medical School, Boston, MA, United States
21 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States

KRAS or NRAS mutations are present in ~50% of multiple myeloma (MM) patients at diagnosis and at higher frequency in relapsed/refractory disease. Pharmacologic RAS inhibitors (RASinh) are clinically active in select solid tumors. We thus evaluated the efficacy of inhibitors targeting specific KRAS mutants (e.g., G12C [MRTX-1257]; G12D [MRTX-1133]), a broader spectrum of KRAS mutants (BI-2865), or multiple mutant and wild-type RAS forms (e.g., RMC-6236, RMC-7977, ADT-007) in preclinical MM models. We integrated in vitro and in vivo pharmacologic approaches, functional genomics, transcriptomics, proteomics and chemical biology screens to define mechanisms that govern RAS inhibitor sensitivity vs. resistance and nominate potential combinations for MM.

We observed that MM cells respond in vitro to RASinh at clinically relevant concentrations. In a panel of ~50 MM lines, sensitivity to RMC-6236 correlates with activating mutation or CRISPR-confirmed dependency for KRAS or NRAS but can also occur in wild-type MM lines with upstream RAS-activating lesions (e.g., activating FGFR3 mutations). Concordant results were observed with short term in vitro treatment of patient-derived MM tumor cells. RNAseq of short-term (8h) in vitro RMC-6236 treatment in 6 MM lines defined a consensus signature of RASinh-downregulated genes that reflects RAS pathway activity: higher baseline levels of this signature in MM patient tumor cells (CoMMpass) correlates with higher R-ISS stage and shorter PFS and OS (even when applied in RAS-wild-type patients); and is progressively increased in relapsing vs. newly diagnosed samples. RASinh monotherapy in vivo (NSG mice) was active against MM lines (XG-7 and KP-6 with mutant-specific KRAS inhibitors; MM.1S and SKMM-1 with RMC-6236), but tumor escape eventually emerged: MM cells isolated at relapse had no changes in their pattern of mutation (WES) and retained ex vivo sensitivity to RASinh retreatment. Clonal tracking studies demonstrated no significant enrichment of DNA barcodes after RASinh treatment, indicating that escape can occur without selection of pre-existing resistant clones. Longitudinal RNAseq and proteomic/phosphoproteomic analyses revealed upregulation of diverse upstream receptors for cytokine/growth factors and other adaptive responses in RASinh-treated MM cells. A total of 36 genome-scale CRISPR knockout (KO) and activation (CRISPRa) screens of RASinh-treatment across 10 MM lines showed heterogeneous, cell-line-specific “resistomes” that did not strictly segregate by RAS mutation, but also exhibited recurrent patterns: CRISPR activation studies identified EGFR, MET, ABCB1, KRAS and SHOC2 as recurrent resistance drivers, whereas KO screens identified LZTR1, TRAF3, PTEN, KEAP1, NF2L1 and additional negative regulators of RAS/MAPK, NF-κB, oxidative stress and PI3K signaling. Shared and inhibitor-specific resistance mechanisms were identified, including selective dependence of RMC-6236 on PPIA (cyclophilin A), consistent with its mechanism of action. Many CRISPR hits overlapped with KRAS inhibitor screens in solid tumors, whereas others appear to be MM-selective. Notably, most of the top differentially expressed genes after RASinh treatment (including known negative-feedback mediators [DUSP6, SPRY4] or known RAS effectors [ETV4, ETV5]) were often not top CRISPR hits in the same MM line, underscoring the value of functional genomics to dissect treatment-induced molecular changes vs. regulators of response. The transcriptional signatures of RASinh treatment in MM cells (in this study) and other neoplasias (publicly available data) exhibited several shared genes, but also many others distinctly identified in MM. Finally, using in vitro pharmacological screens, we identified sensitizers and confirmed in vivo (NSG mice) that RMC-6236 combined with lenalidomide is more active than either agent alone.

Collectively, our studies indicate that response to pharmacological RAS inhibitors in MM is determined by heterogeneous and potentially cooperating mechanisms of escape, including treatment-induced non-genomic molecular “rewiring”, microenvironment-derived protection, and genomic lesions. These findings map the complex molecular landscape underlying RASinh responses and can inform personalized clinical development of these agents in MM. Our findings provide a framework for the determination of biomarkers, rational drug combination strategies and clinical translation of RAS-targeted treatment in MM.

Torsten Steinbrunn, MD, PhD: Janssen - Other (including travel support)